Related Experiment Video

Updated: Aug 6, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Control of skin carcinoma via sonidegib-loaded transbilosomes

Rowayda Mohamed Ahmed1, Maha M Ghalwash2, Amr Gamal Fouad3

  • 1Department of Anatomy and Embryology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.

Journal of Drug Targeting
|July 23, 2026
PubMed

Insights

This study developed an intratumor Sonidegib-loaded transbilosomes (SLT) formulation to enhance skin carcinoma treatment. The SLT formulation improved drug delivery, reduced side effects, and significantly shrank tumors.

Area of Science:

  • Dermatology
  • Nanotechnology
  • Pharmacology

Background:

  • Skin carcinoma is characterized by uncontrolled abnormal skin cell proliferation.
  • Sonidegib (SDB), a Hedgehog pathway inhibitor, treats skin carcinoma but has poor bioavailability and systemic toxicity.
  • Current limitations necessitate improved drug delivery systems for Sonidegib.

Purpose of the Study:

  • To develop and optimize an intratumor Sonidegib-loaded transbilosomes (SLT) formulation.
  • To enhance localized therapeutic efficacy and mitigate systemic adverse effects of Sonidegib.
  • To evaluate the safety and efficacy of the SLT formulation in a preclinical skin carcinoma model.

Main Methods:

  • Formulation development and optimization of SLT using Design-Expert® software.
  • Evaluation of drug release kinetics and pharmacokinetics of SLT.
  • Assessment of intratumor retention, in vivo efficacy, and safety in a DMBA-induced skin carcinoma rat model.

Main Results:

  • The optimized SLT formulation demonstrated a 68.87% reduction in drug release compared to free SDB.
  • Intratumor SLT showed a 7.78-fold increase in relative systemic bioavailability versus oral SDB.
  • In vivo studies revealed an 84.22% reduction in tumor volume with the SLT formulation and a favorable safety profile.

Conclusions:

  • Intratumor SLT formulation effectively improves localized delivery and therapeutic efficacy for skin carcinoma.
  • The developed SLT formulation mitigates systemic toxicity associated with Sonidegib treatment.
  • Intratumor SLT represents a promising strategy for managing skin carcinoma with enhanced safety and efficacy.
Keywords:
Skin carcinomaintratumorsonidegibtargetingtransbilosomes

More Related Videos

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation14:10

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Published on: December 15, 2010

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.